On Nov 07, major Wall Street analysts update their ratings for $Gilead Sciences (GILD.US)$, with price targets ranging from $95 to $105.
J.P. Morgan analyst Chris Schott maintains with a buy rating, and adjusts the target price from $100 to $105.
Barclays analyst Carter Gould maintains with a hold rating, and adjusts the target price from $76 to $95.
Wells Fargo analyst Mohit Bansal maintains with a buy rating, and maintains the target price at $105.
Jefferies analyst Michael Yee maintains with a buy rating, and maintains the target price at $105.
TD Cowen analyst Tyler Van Buren maintains with a buy rating, and adjusts the target price from $85 to $95.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
The company experienced a sales surge, bolstered by robust performance across its HIV product range and revenues for Veklury surpassing expectations. The company's HIV segment demonstrated vigor this quarter, marked by sustained volume expansion and a positive product mix.
The company showcased a stronger than anticipated performance in Q3, bolstered not only by Veklury but also by Biktarvy.
Gilead has exhibited a 'consistent steady performance' this quarter, demonstrating the enduring robustness of its HIV franchise. This reliable strength is seen as a positive sign in advance of the company's forthcoming U.S. submission of lenacapavir for PrEP.
The firm noted that another solid quarter was recorded and mentioned that the revised target is mainly due to the anticipation that the Sunlenca PrEP opportunity, along with Livdelzi in PBC, may present new commercial prospects.
Gilead's recent financial results exceeded expectations, propelled by strong performance in its HIV segment and significant contributions from Veklury, coupled with lower operational expenses than anticipated. Additionally, the company's management has expressed optimism regarding the PrEP launch and forthcoming ASH data.
Here are the latest investment ratings and price targets for $Gilead Sciences (GILD.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月7日，多家华尔街大行更新了$吉利德科学 (GILD.US)$的评级，目标价介于95美元至105美元。
摩根大通分析师Chris Schott维持买入评级，并将目标价从100美元上调至105美元。
巴克莱银行分析师Carter Gould维持持有评级，并将目标价从76美元上调至95美元。
富国集团分析师Mohit Bansal维持买入评级，维持目标价105美元。
富瑞集团分析师Michael Yee维持买入评级，维持目标价105美元。
TD Cowen分析师Tyler Van Buren维持买入评级，并将目标价从85美元上调至95美元。
此外，综合报道，$吉利德科学 (GILD.US)$近期主要分析师观点如下：
公司经历了销售激增，得益于HIV产品区间的强劲表现，以及Veklury的收入超出预期。本季度公司的HIV部门表现强劲，成交量持续扩张，产品组合积极。
公司在第三季度展示了比预期更强的表现，不仅得益于Veklury，还得益于Biktarvy。
吉利德在本季度展示了“持续稳健表现”，展示了其HIV特许经营的持久稳健性。这种可靠的实力被视为公司即将提交Sunlenca PrEP用于PBC的美国申请前的积极信号。
公司指出另一个稳健的季度已记录，并提到修正的目标主要是由于预计Sunlenca PrEP机会，以及Livdelzi在PBC中，可能带来新的商业前景。
吉利德最近的财务业绩超出预期，得益于其HIV部门的强劲表现以及Veklury的重要贡献，再加上低于预期的运营费用。此外，公司管理层对PrEP的推出和即将到来的ASH数据表示乐观。
以下为今日9位分析师对$吉利德科学 (GILD.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
